Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07

Trial Profile

A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duvelisib (Primary) ; Ofatumumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Infinity Pharmaceuticals; Verastem Oncology
  • Most Recent Events

    • 08 Oct 2019 Planned End Date changed from 1 Jun 2019 to 1 Jul 2020.
    • 08 Oct 2019 Planned primary completion date changed from 1 May 2019 to 1 Jul 2020.
    • 07 Mar 2019 According to a Verastem Oncology Media Release, data from this study and NCT01882803, NCT02004522,,NCT01476657 was presented at the 23rd Annual International Congress on Hematologic Malignancies (ICHM), which took place February 28 to March 3, 2019, in Miami, Florida.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top